Med. Pro Praxi 2004; 1: 19-21

Fytoestrogeny

MUDr. Marie Vrzáňová1, MUDr. Jana Heresová CSc2,3
1 Interní klinika fakultní nemocnice Motol a 2. lékařské fakulty Univerzity Karlovy v Praze
2 Endokrinologický ústav, Praha
3 Klinika nukleární medicíny UK 2. LF Praha a FN Motol

Keywords: fytoestrogeny, izoflavony, estrogeny, menopauza.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrzáňová M, Heresová J. Fytoestrogeny. Med. praxi. 2004;2(1):19-21.

Fytoestrogeny (FE) jsou přirozené aktivní látky obsažené v rostlinách, u vyšších živočichů a u člověka jsou charakterizovány afinitou k estrogennímu receptoru (ER). Chemickou strukturou jsou fytoestrogeny vzdálené estrogenům, společným rysem je fenolové jádro v molekule, které umožňuje vazbu na ER s následnou metabolickou aktivitou a vylučováním podobně jako endogenní estrogeny. Nejznámější skupinou fytoestrogenů jsou izoflavony, kumestany, flavony, lignany a další, liší se svými estrogenními vlastnostmi. Rizika hormonální substituční léčby u žen v klimakteriu jsou prokazatelná, FE vytváří možnosti alternativní léčby u žen, které estrogeny nemohou užívat.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Barnes S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat 1997; 46 (2-3): 169-179. Go to original source... Go to PubMed...
    2. Grady D, et al. Cardiovascular disease outcomes during 6,8 years of hormone terapy JAMA 2002; 288 (7): 49-57. Go to original source... Go to PubMed...
    3. Herrington DM, Reboussin DM, Klein KP, et al. The estrogen replacement and aterosclerosis (ERA) study - study disign and baseline characteristics of the cohort. Control Clin Trials 2000; 21 (3): 257-285. Go to original source... Go to PubMed...
    4. Hulley S, Grady D, Bush T, et al. The heart and estrogen/progestin replacement study (HERS) research group. JAMA 1998; 280 (7): 605-613. Go to original source... Go to PubMed...
    5. Chi-Ling Chen, Weis NS, Newcomb P, Barlow W. White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002; 287 (6): 734-737. Go to original source... Go to PubMed...
    6. Liggins J, Bluck IJ,Runswick S, Atkinson C, Coward WA, Bingham SA. Daidzein and genistein contents of vegetables. Br J Nutr 2000; 84 (5): 717-725. Go to original source... Go to PubMed...
    7. Nagata C, Takatsuka N, Kawakami N, Shimizu H. Soy product intake and premenopausal hysterectomy in follow-up study of Japanes women. Eur J Clin Nutr 2001; 55 (9): 773-777. Go to original source... Go to PubMed...
    8. Strnad P. Závěrečná zpráva půlroční studie pro firmu Biovit impex Co. s přípravkem Swis Herbal Remedies Ltd., Kanada- SwisEstrovone 75 mg 2001, Gynekologicko-porodnická klinika FN Motol, Praha.
    9. Stárka L, et al. Aktuální endokrinologie. Maxdorf 1999: 738: (Fytoestrogeny 189-198).
    10. Šormová I. Fytoestrogeny v léčbě klimakterického syndromu. Klimakterická medicína 2003; 1,8: 6-8.
    11. Wang C, Kurzer MS. Efekt of phytoestrogens on DNA synthesin in MCF-7 cells in the presence of estradiol or growth factors. Breast Cancor Res Treat 2000; 62 (1): 35-49.
    12. Writing group for the Women´s health initiative investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288 (7): 321-333.
    13. Xu X, Duncan AM, Merz BE, Kurzer MS. Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women. Cancer Epidemiol. Biomarkers Prev 1998; 7 (12): 1101-1108. Go to PubMed...
    14. Zand RS, Jenkins DJ, Diamandis EP. Steroid hormone aktivity of flavonoids and related compounds. Nutr Cancer 1998; 31 (2): 90-100.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.